Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-
Targeting Antibody Demonstrates Potential to Become a Best-in-Class Therapy for Obesity
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 18, 2026 /PRNewswire/ — Harbour BioMed (the “Company”; H… [7272 chars]
